{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:01:02Z","timestamp":1793642462946,"version":"4.5.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012621","name":"University College London Hospitals Biomedical Research Centre","doi-asserted-by":"publisher","award":["WO2016\/139487"],"award-info":[{"award-number":["WO2016\/139487"]}],"id":[{"id":"10.13039\/501100012621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012621","name":"University College London Hospitals Biomedical Research Centre","doi-asserted-by":"publisher","award":["WO2019\/220109"],"award-info":[{"award-number":["WO2019\/220109"]}],"id":[{"id":"10.13039\/501100012621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ymthe.2023.03.020","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T08:40:18Z","timestamp":1679388018000},"page":"2089-2104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4686-6806","authenticated-orcid":false,"given":"Evangelia","family":"Kokalaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Grothier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Hazelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayya","family":"Manzoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eren","family":"Costu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bulek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saket","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Gannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind","family":"Gealy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Stanczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Rizou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Robson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El-Kholy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Baldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Righi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Sillibourne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimobi","family":"Onuoha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Cordoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8347-9867","authenticated-orcid":false,"given":"Martin","family":"Pule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2023.03.020_bib1","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","article-title":"CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date","volume":"127","author":"Park","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2023.03.020_bib2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/bjh.13340","article-title":"CD19 chimeric antigen receptor T\u00a0cell therapy for haematological malignancies","volume":"169","author":"Ghorashian","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymthe.2023.03.020_bib3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2023.03.020_bib4","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2023.03.020_bib5","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2023.03.020_bib6","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.3324\/haematol.2017.183459","article-title":"Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma","volume":"103","author":"Shalabi","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2023.03.020_bib7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-3083.2002.01063.x","article-title":"Expression and function of CD22, a B-cell restricted molecule","volume":"55","author":"Moyron-Quiroz","year":"2002","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.ymthe.2023.03.020_bib8","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/intimm\/9.10.1571","article-title":"Analysis of murine CD22 during B cell development: CD22 is expressed on B cell progenitors prior to IgM","volume":"9","author":"Stoddart","year":"1997","journal-title":"Int. Immunol."},{"key":"10.1016\/j.ymthe.2023.03.020_bib9","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1182\/blood.V71.5.1480.1480","article-title":"Expression and structure of CD22 in acute leukemia","volume":"71","author":"Bou\u00e9","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2023.03.020_bib10","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1084\/jem.181.4.1581","article-title":"Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand","volume":"181","author":"Engel","year":"1995","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2023.03.020_bib11","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1309\/KPXNVR7X4AMENBBE","article-title":"Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-Cell chronic lymphoproliferative disorders from admixed benign B cells in four-color multiparameter flow cytometry","volume":"123","author":"Huang","year":"2005","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ymthe.2023.03.020_bib12","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2023.03.020_bib13","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/leu.2008.303","article-title":"Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases","volume":"23","author":"Chevallier","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2023.03.020_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/10428194.2010.529206","article-title":"Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia","volume":"52","author":"Piccaluga","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ymthe.2023.03.020_bib15","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ymthe.2023.03.020_bib16","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","article-title":"Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children\u2019s Oncology Group Pilot Study","volume":"26","author":"Raetz","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2023.03.020_bib17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12185-011-0900-1","article-title":"Flow cytometric analysis of de novo acute lymphoblastic leukemia in childhood: report from the Japanese Pediatric Leukemia\/Lymphoma Study Group","volume":"94","author":"Iwamoto","year":"2011","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.ymthe.2023.03.020_bib18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/cyto.b.21512","article-title":"Composite mantle cell lymphoma and chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"94","author":"Sun","year":"2018","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.ymthe.2023.03.020_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/08820130500496878","article-title":"A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry","volume":"35","author":"Olejniczak","year":"2006","journal-title":"Immunol. Invest."},{"key":"10.1016\/j.ymthe.2023.03.020_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T\u00a0cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2023.03.020_bib21","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2023.03.020_bib22","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41467-017-00836-6","article-title":"Molecular basis of human CD22 function and therapeutic targeting","volume":"8","author":"Ere\u00f1o-Orbea","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2023.03.020_bib23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1084\/jem.173.1.137","article-title":"cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions","volume":"173","author":"Wilson","year":"1991","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2023.03.020_bib24","doi-asserted-by":"crossref","first-page":"e104730","DOI":"10.15252\/embj.2020104730","article-title":"Rewired signaling network in T\u00a0cells expressing the chimeric antigen receptor (CAR)","volume":"39","author":"Dong","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.ymthe.2023.03.020_bib25","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4161\/mabs.1.3.8113","article-title":"Identification and characterization of fully human anti-CD22 monoclonal antibodies","volume":"1","author":"Xiao","year":"2009","journal-title":"MAbs"},{"key":"10.1016\/j.ymthe.2023.03.020_bib26","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T\u00a0cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2023.03.020_bib27","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T\u00a0cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2023.03.020_bib28","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T\u00a0cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2023.03.020_bib29","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.21.00917","article-title":"Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"39","author":"Roddie","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2023.03.020_bib30","first-page":"185","article-title":"Accelerated antibody discovery targeting the SARS-CoV-2 spike protein for COVID-19 therapeutic potential","volume":"4","author":"Mullen","year":"2021","journal-title":"Antib. Ther."},{"key":"10.1016\/j.ymthe.2023.03.020_bib31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000229694","article-title":"The effect of various hormones on the serum level of anaphylactic antibody in the rat","volume":"29","author":"Oettgen","year":"1966","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"10.1016\/j.ymthe.2023.03.020_bib32","first-page":"3928","article-title":"Bypassing immunization: optimized design of \u201cdesigner T\u00a0cells\u201d against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA","volume":"5","author":"Nolan","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.020_bib33","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2023.03.020_bib34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2144\/btn-2021-0079","article-title":"A compact and simple method of achieving differential transgene expression by exploiting translational readthrough","volume":"72","author":"Sillibourne","year":"2022","journal-title":"Biotechniques"},{"key":"10.1016\/j.ymthe.2023.03.020_bib35","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","article-title":"Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T\u00a0cells","volume":"3","author":"Frigault","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2023.03.020_bib36","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T\u00a0cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2023.03.020_bib37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2023.03.020_bib38","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2023.03.020_bib39","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-Targeted T\u00a0cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2023.03.020_bib40","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood.V126.23.681.681","article-title":"Durable remissions in children with relapsed\/refractory ALL treated with T\u00a0cells engineered with a CD19-targeted chimeric antigen receptor (CTL019)","volume":"126","author":"Grupp","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2023.03.020_bib41","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T\u00a0cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2023.03.020_bib42","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T\u00a0cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2023.03.020_bib43","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2023.03.020_bib44","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2023.03.020_bib45","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2023.03.020_bib46","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2023.03.020_bib47","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1182\/blood-2018-99-120206","article-title":"Target antigen downregulation and other mechanisms of failure after axicabtagene ciloleucel (CAR19) therapy","volume":"132","author":"Oak","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2023.03.020_bib48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00262-004-0572-2","article-title":"Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunol","volume":"54","author":"DiJoseph","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2023.03.020_bib49","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2023.03.020_bib50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1006\/smim.2000.0203","article-title":"Cytoskeletal polarization and redistribution of cell-surface molecules during T\u00a0cell antigen recognition","volume":"12","author":"Anton van der Merwe","year":"2000","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.ymthe.2023.03.020_bib51","doi-asserted-by":"crossref","first-page":"eabl3995","DOI":"10.1126\/sciimmunol.abl3995","article-title":"Size-dependent activation of CAR-T cells","volume":"7","author":"Xiao","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ymthe.2023.03.020_bib52","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.4049\/jimmunol.169.2.1110","article-title":"TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity","volume":"169","author":"Chames","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2023.03.020_bib53","doi-asserted-by":"crossref","first-page":"7647","DOI":"10.4049\/jimmunol.173.12.7647","article-title":"T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T\u00a0cell activation against antigen-positive target cells but decreases selectivity","volume":"173","author":"Chmielewski","year":"2004","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2023.03.020_bib54","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T\u00a0cells","volume":"19","author":"Hudecek","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.020_bib55","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-15-0139","article-title":"Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity","volume":"75","author":"Caruso","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.020_bib56","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T\u00a0cells exhibit an increased therapeutic index against tumors in mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.020_bib57","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/leu.2016.35","article-title":"High-affinity FR\u03b2-specific CAR T\u00a0cells eradicate AML and normal myeloid lineage without HSC toxicity","volume":"30","author":"Lynn","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2023.03.020_bib58","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/CJI.0b013e3180de5d90","article-title":"Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction","volume":"30","author":"Turatti","year":"2007","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.ymthe.2023.03.020_bib59","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.4049\/jimmunol.178.7.4650","article-title":"T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T\u00a0cells","volume":"178","author":"Hombach","year":"2007","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2023.03.020_bib60","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","article-title":"Retargeting of human T\u00a0cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor","volume":"180","author":"Wilkie","year":"2008","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2023.03.020_bib61","doi-asserted-by":"crossref","first-page":"7028","DOI":"10.4049\/jimmunol.180.10.7028","article-title":"Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane","volume":"180","author":"James","year":"2008","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2023.03.020_bib62","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-021-01326-5","article-title":"Antigen-independent activation enhances the efficacy of 41BB co-stimulated CD22 CAR T\u00a0cells","volume":"27","author":"Singh","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2023.03.020_bib63","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2023.03.020_bib64","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies","volume":"135","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2023.03.020_bib65","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood-2018-99-110142","article-title":"Phase I experience with a Bi-specific CAR targeting CD19 and CD22 in adults with B-cell malignancies","volume":"132","author":"Hossain","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2023.03.020_bib66","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.2022015795","article-title":"CD19\/22 CAR T\u00a0cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR","volume":"140","author":"Shalabi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2023.03.020_bib67","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1089\/104303401753153947","article-title":"Systematic determination of the packaging limit of lentiviral vectors","volume":"12","author":"Kumar","year":"2001","journal-title":"Hum. Gene Ther."}],"updated-by":[{"DOI":"10.1016\/j.ymthe.2023.12.006","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000}}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623001417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623001417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T17:04:12Z","timestamp":1707584652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001623001417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":67,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1525001623001417"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.03.020","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}]}}